The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients

Background: Myelin oligodendrocyte glycoprotein (anti-MOG) antibody was reported in anti-aquaporin-4 (anti-AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD) patients. Objectives: To describe clinical phenotypes associated with anti-MOG. Methods: Seventy consecutive Thai patients with inflammatory idiopathic demyelinating central nervous system disorders (IIDCD) who were previously anti-AQP4 seronegative were tested for anti-MOG. Results: Anti-MOG was positive in six patients, representing 20.7% of the IIDCD anti-AQP4 seronegative patients with a non-multiple sclerosis phenotype, and most had relapses. All first presented with optic neuritis with good visual recovery after treatment. Conclusions: Anti-MOG positive patients may have manifestations that mimic NMOSD but differ in their course and prognosis from anti-AQP4 positive NMOSD.

[1]  T. Nakazawa,et al.  MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  K. Fujihara,et al.  Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report , 2014, BMC Neurology.

[3]  T. Kezuka,et al.  Distinction between MOG antibody–positive and AQP4 antibody–positive NMO spectrum disorders , 2014, Neurology.

[4]  Masami Tanaka,et al.  Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system , 2014, Journal of Neuroimmunology.

[5]  Jacqueline A Palace,et al.  Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. , 2014, JAMA neurology.

[6]  K. Rostásy,et al.  The spectrum of MOG autoantibody-associated demyelinating diseases , 2013, Nature Reviews Neurology.

[7]  Jacqueline A Palace,et al.  Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype , 2012, Neurology.

[8]  Y. Itoyama,et al.  Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease , 2012 .

[9]  B. Weinshenker,et al.  The spectrum of neuromyelitis optica , 2007, The Lancet Neurology.

[10]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.